Zydus Cadila gets last endorsement from USFDA for Meclizine Hydrochloride Tablets

Zydus Cadila gets last endorsement from USFDA for Meclizine Hydrochloride Tablets

Overview

  • Post By : Kumar Jeetendra

  • Source: Agencies

  • Date: 24 Jun,2020

Zydus Cadila has gotten last endorsement from the USFDA to showcase Meclizine Hydrochloride Tablets (US RLD: Antivert Tablets) in the qualities of 12.5 mg and 25 mg.

The medication will be produced at the gathering’s assembling office at SEZ, Ahmedabad, Cadila said in the recording.

Meclizine is an antihistamine that is utilized to forestall and treat queasiness, spewing, and discombobulation brought about by movement ailment. It might likewise be utilized to decrease discombobulation and loss of parity (vertigo) brought about by inward ear issues.

The gathering presently has 292 endorsements and has so far documented more than 390 ANDAs since the beginning of the recording procedure in FY2003-04.

Cadila Healthcare Ltd is as of now exchanging at Rs367.35, up by Rs0.4 or 0.11% from its past shutting of Rs366.95 on the BSE.

The scrip opened at Rs370 and has contacted a high and low of Rs373.35 and Rs363.15 separately.

About Author